Gilead Sciences Unveils Positive Data on HIV Prevention Shot
Overview of Gilead's HIV Prevention Shot
Gilead Sciences has recently revealed positive findings regarding its HIV prevention shot, lenacapavir. In a substantial clinical trial involving over 3,200 participants, including cisgender men, transgender women, and gender nonbinary individuals, lenacapavir has demonstrated a 96% reduction in HIV infections.
Significance of the Results
This remarkable outcome signifies a promising step forward in HIV prevention. With lenacapavir being administered twice a year, this innovative shot offers an effective option for those at high risk of HIV infection.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.